Virataz R Tablet (Atazanavir and Ritonavir)

Virataz R Tablet is an antiretroviral medicine as it contains active ingredients Atazanavir and Ritonavir that belongs to the protease inhibitors class of drugs. Doctor prescribes it to treat HIV-1 infection. Virataz R works by inhibiting the protease enzyme that promotes replication of human immunodeficiency virus. Thereby, slow down the virus multiplication and spread in the body, which results in lowering the progression of HIV infection. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

HIV

Virataz R(Atazanavir and Ritonavir) is a strong antiviral medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects include:
● Nausea, vomiting
● Diarrhea
● Abdominal pain
● Rash
● Fatigue
● Neurological disturbances (tingling, numbness, chilling)
● Headache
● Fever
● Depression
● Insomnia
● Dizziness
● Muscle pain

Take Virataz R Tablet(Atazanavir and Ritonavir) in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.

● Noor, M. A., Parker, R. A., O'Mara, E., Grasela, D. M., Currie, A., Hodder, S. L., ... & Haas, D. W. (2004). The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. Aids, 18(16), 2137-2144.
● Daar, E. S., Tierney, C., Fischl, M. A., Sax, P. E., Mollan, K., Budhathoki, C., ... & AIDS Clinical Trials Group Study A5202 Team*. (2011). Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Annals of internal medicine, 154(7), 445-456.
● Burger, D. M., Agarwala, S., Child, M., Been-Tiktak, A., Wang, Y., & Bertz, R. (2006). Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrobial agents and chemotherapy, 50(10), 3336-3342.
● Cohen, C., Nieto-Cisneros, L., Zala, C., Fessel, W. J., Gonzalez-Garcia, J., Gladysz, A., ... & BMS, AI424‐043 Study Group. (2005). Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Current medical research and opinion, 21(10), 1683-1692.
● Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E., Lazzarin, A., ... & Wilber, R. (2005). Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids, 19(7), 685-694.